{"filing":{"accession_number":"0000950103-26-010269","cik":"0001764046","ticker":"CLVT","company_name":"CLARIVATE PLC","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"dp249688_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1764046/000095010326010269/dp249688_8k.htm"},"events":[{"id":16233,"run_id":14486,"accession_number":"0000950103-26-010269","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Clarivate entered into a Stock and Asset Purchase Agreement to sell its Life Sciences and Healthcare business to an Altaris affiliate for $600 million in aggregate consideration, comprising cash, deferred payments, and a senior note.","company_name":"CLARIVATE PLC","ticker":"CLVT","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14273,"accession_number":"0000950103-26-010269","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Clarivate has entered into a Stock and Asset Purchase Agreement to sell its Life Sciences and Healthcare business to an Altaris affiliate for $600 million in aggregate consideration (cash, deferred payments, and a senior note). This is a material disposition of a business segment disclosed under Item 1.01, representing a significant capital transaction that would materially affect investor assessment of the company's asset base and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:56:03.811865+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":16234,"run_id":14486,"accession_number":"0000950103-26-010269","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Clarivate entered into a retention agreement with Henry Levy, President of Life Sciences \u0026 Healthcare, providing for full vesting of unvested RSUs upon transaction closing, cancellation of performance share units, and severance payments of 18 months' base salary and target bonus plus COBRA payments if terminated without cause within six months post-closing.","company_name":"CLARIVATE PLC","ticker":"CLVT","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14274,"accession_number":"0000950103-26-010269","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on a retention agreement entered into with Henry Levy, Clarivate's President of Life Sciences \u0026 Healthcare, containing compensatory arrangements including: (i) full vesting of unvested RSUs upon transaction closing, (ii) cancellation of performance share units, and (iii) severance payments of 18 months' base salary and target bonus plus COBRA payments if terminated without cause within six months post-closing. This is a classic executive compensation arrangement tied to a material transaction, distinct from a departure or appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:56:03.811865+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14273,"accession_number":"0000950103-26-010269","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Clarivate has entered into a Stock and Asset Purchase Agreement to sell its Life Sciences and Healthcare business to an Altaris affiliate for $600 million in aggregate consideration (cash, deferred payments, and a senior note). This is a material disposition of a business segment disclosed under Item 1.01, representing a significant capital transaction that would materially affect investor assessment of the company's asset base and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:56:03.811865+00:00","company_name":"CLARIVATE PLC","ticker":"CLVT","filing_date":"2026-07-06"},{"id":14274,"accession_number":"0000950103-26-010269","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on a retention agreement entered into with Henry Levy, Clarivate's President of Life Sciences \u0026 Healthcare, containing compensatory arrangements including: (i) full vesting of unvested RSUs upon transaction closing, (ii) cancellation of performance share units, and (iii) severance payments of 18 months' base salary and target bonus plus COBRA payments if terminated without cause within six months post-closing. This is a classic executive compensation arrangement tied to a material transaction, distinct from a departure or appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T18:56:03.811865+00:00","company_name":"CLARIVATE PLC","ticker":"CLVT","filing_date":"2026-07-06"}]}